Supernus Pharmaceuticals Inc. (SUPN)
$51.53
$-0.75
(-1.43%)
As on 08-May-2026 16:00EDT
Market cap
$2,991 Mln
Revenue (TTM)
$777 Mln
P/E Ratio
--
P/B Ratio
2.8
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0 %
-
ROCE
-- %
-
Industry P/E
25.89
-
EV/EBITDA
59
-
Debt to Equity
0
-
Book Value
$18.5
-
EPS
$-0.5
-
Face value
--
-
Shares outstanding
58,039,721
10 Years Aggregate
CFO
$986.86 Mln
EBITDA
$1,107.79 Mln
Net Profit
$648.84 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Supernus Pharmaceuticals (SUPN)
| 3.7 | 1.1 | 4.4 | 66.5 | 12.0 | 11.9 | 13.0 |
|
BSE Sensex
| -8.7 | 3.6 | -7.5 | -4.2 | 8.2 | 9.5 | 11.9 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Supernus Pharmaceuticals (SUPN)
| 37.4 | 24.7 | -18.9 | 22.3 | 15.9 | 6.1 | -28.6 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Supernus Pharmaceuticals (SUPN)
|
51.5 | 2,990.8 | 776.8 | -29.0 | -10.4 | -2.7 | -- | 2.8 |
| 13.2 | 4,211.1 | 3,045.9 | 122.4 | 13.8 | -- | 35.7 | 105.4 | |
| 41.0 | 5,252.7 | 1,029.0 | 133.3 | 14.5 | 32.7 | 38.3 | 14.2 | |
| 217.4 | 11,186.3 | 708.2 | -188.3 | -25.6 | -293.5 | -- | 210.8 | |
| 67.4 | 13,199.1 | 566.0 | -725.9 | -89.0 | -- | -- | 123.7 | |
| 52.3 | 5,612.3 | 769.1 | 47.9 | 5.4 | 7.5 | 149.4 | 8.8 | |
| 23.7 | 11,812.0 | 4,893.0 | -242.0 | -1.5 | -3.7 | -- | 1.7 | |
| 8.1 | 5,512.7 | 7,682.7 | 438.7 | 15.9 | 7.5 | 11.7 | 0.9 | |
| 13.4 | 3,497.8 | 6,163.0 | 246.0 | 15.7 | 54.3 | 14.3 | 3.9 | |
| 56.9 | 3,645.4 | 409.5 | -81.3 | -20.1 | -17.5 | -- | 7.8 |
Shareholding Pattern
View DetailsAbout Supernus Pharmaceuticals (SUPN)
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated... for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; and SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland. Read more
-
Founder, President, CEO, Secretary & Director
Mr. Jack A. Khattar
-
Founder, President, CEO, Secretary & Director
Mr. Jack A. Khattar M.B.A.
-
Headquarters
Rockville, MD
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Supernus Pharmaceuticals (SUPN)
What is the current share price of Supernus Pharmaceuticals Inc (SUPN) Today?
The share price of Supernus Pharmaceuticals Inc (SUPN) is $51.53 (NASDAQ) as of 08-May-2026 16:00 EDT. Supernus Pharmaceuticals Inc (SUPN) has given a return of 11.97% in the last 3 years.
What is the current PB & PE ratio of Supernus Pharmaceuticals Inc (SUPN)?
Since, TTM earnings of Supernus Pharmaceuticals Inc (SUPN) is negative, P/E ratio is not available.
The P/B ratio of Supernus Pharmaceuticals Inc (SUPN) is 2.78 times as on 08-May-2026, a 55 discount to its peers’ median range of 6.11 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-73.93
|
2.68
|
|
2024
|
27.64
|
1.97
|
|
2023
|
1,210.77
|
1.73
|
|
2022
|
36.48
|
2.50
|
|
2021
|
29.07
|
1.90
|
What is the 52 Week High and Low of Supernus Pharmaceuticals Inc (SUPN)?
The 52-week high and low of Supernus Pharmaceuticals Inc (SUPN) are Rs 59.68 and Rs 30.44 as of 10-May-2026.
What is the market cap of Supernus Pharmaceuticals Inc (SUPN)?
Supernus Pharmaceuticals Inc (SUPN) has a market capitalisation of $ 2,991 Mln as on 08-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Supernus Pharmaceuticals Inc (SUPN)?
Before investing in Supernus Pharmaceuticals Inc (SUPN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.